Actively Recruiting
Evaluation of BRUDYGLAUCO (DHA + Citicoline) in Patients With Glaucoma
Led by Institut Catala de Retina · Updated on 2026-01-14
108
Participants Needed
2
Research Sites
112 weeks
Total Duration
On this page
Sponsors
I
Institut Catala de Retina
Lead Sponsor
H
Hospital de la Esperanza
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aims to evaluate the effects of BrudyGlauco, a nutritional supplement containing DHA (docosahexaenoic acid) and citicoline, on visual function in people with glaucoma. Glaucoma is a progressive optic neuropathy that can lead to vision loss. Current treatments focus on lowering eye pressure, but there are other pathogenic factors and the use of additional therapies that could protect or regenerate the optic nerve would be beneficial. This is a randomized, double-blind, placebo-controlled, and multicenter clinical trial. Participants will be randomly assigned to receive either BrudyGlauco or a placebo for 12 months. The study will assess changes in visual field, safety, and treatment adherence. The trial is being conducted at the Institut Català de Retina (ICR) and Hospital de la Esperanza. Participants will undergo regular eye exams, visual field tests, and follow-ups to monitor potential improvements in visual function. The results of this study will help determine if BrudyGlauco can provide neuroprotective benefits for people with glaucoma and improve their quality of life.
CONDITIONS
Official Title
Evaluation of BRUDYGLAUCO (DHA + Citicoline) in Patients With Glaucoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with chronic glaucoma (primary or secondary, open-angle or closed-angle) in at least one eye, showing structural damage confirmed by OCT or fundus photography.
- Functional damage with at least 3 contiguous abnormal points outside the 95% confidence limit on visual field pattern deviation map.
- At least 4 reliable visual field tests before enrollment.
- Age between 50 and 75 years.
- If both eyes qualify, the eye with the worst Mean Deviation (MD) will be selected as the study eye.
You will not qualify if you...
- Use of any vitamin or nutraceutical supplements in the month before screening.
- Conditions affecting visual field testing such as neurological diseases, retinal diseases, advanced cataracts, or treatment with Lyrica (Pregabalin).
- Hypersensitivity to acetylsalicylic acid (aspirin) due to cross-reactivity risk with citicoline.
- Eye surgery or laser treatment in the 3 months prior to enrollment or planned during the study.
- Visual field Mean Deviation worse than -20 dB or better than -3 dB.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Institut Català de Retina
Barcelona, Barcelona, Spain, 08022
Actively Recruiting
2
Hospital del Mar | Centre Esperança
Barcelona, Barcelona, Spain, 08024
Not Yet Recruiting
Research Team
A
Alfonso Antón Lopez Antón Lopez, Prof MD PhD
CONTACT
E
Estela del Mar Sánchez Sotano, Biomedical science
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here